i-cor®: The first circulatory support system to pump in synchrony with the heart

With Synchronized Cardiac Assist i-cor® opens a new chapter in circulatory support

Mannheim, Germany, (PresseBox) - Xenios AG announces the introduction of ii-cor® - ts new business unit for interventional cardiology - and of its new circulatory support system.

With Synchronized Cardiac Assist i-cor® is the first system to synchronize mechanical circulatory support with the heartbeat. This innovation opens up new therapy options for patients suffering cardiogenic shock, and to bridge patients across high-risk interventions in the cardiac cath lab.

The technology, which is based on a miniaturized pulsatile pump for physiological cardiac support, combines myocardial protection and organ perfusion by assisting the weakened heart with synchronized pulses. With this ECG-triggered pulsation i-cor® actively improves coronary blood flow and limits afterload compared with conventional methods.

Pulsatile perfusion is essential to endothelial function which ensures adequate tissue perfusion in the organs. Maintaining organ function serves to prevent multiorgan failure and to improve clinical outcomes. Oxygenation and CO2 removal are integrated functions of i-cor®. Thus i-cor® offers physiological circulatory support, protection and safety during interventions in the cardiac cath lab, and for the management of cardiogenic shock in the ICU and the cath lab.

Website Promotion

Xenios AG

Xenios is dedicated to translating medical need into pioneering therapies and devices together with physicians, caregivers and patients. The holding represents a fast paced, sustainable group of companies with a robust technology base and an ambitious product pipeline. Xenios strives to be the technology and market leader in extracorporeal therapies. The core technology platforms are artificial lungs, blood pumps, vascular access devices, temperature control, and biocompatible surfaces. The Xenios brands, Novalung, Medos, icor® and Xenios Pediatrics, provide extracorporeal therapy systems that respond to the medical need in pulmonary and cardiac failure. Xenios AG was founded in 2013 by Novalung GmbH and Medos AG.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.